Patent & IP news for October 9, 2009

Patent Litigations

  • No new litigations this day!



Patent & IP Blogs

post image Patent Litigation Weekly: Eolas in Texas, Triune Star fee award, and Guardian Media saga moves to appeals court from

For Eolas, a Texas address, Dallas lawyers, and Plano targets. Eolas Technology, a company built on a patent that originated at the University of California, has gone Texan. Eolas—having settled a previous infringement suit ...

Share via E–mail | Twitter | Facebook

post image My hut's better than your hut: Patenting the Sukkah from

It's been over two weeks since my last post -- a long hiatus for 12:01. The lag is partly attributable to workplace demands and converging deadlines. While blogging is fun and often related to ...

Share via E–mail | Twitter | Facebook

post image Friday factualities from

Make Friday your day for checking the list of forthcoming events in the IPKat's side bar. As ever, this week contains some new items. We might even see you at one (or more) of ...

Share via E–mail | Twitter | Facebook

USPTO rescinds patent claim and continuation rules from

On October 8, after more than two years of controversy and litigation, the USPTO announced that it will rescind the proposed rules that sought to limit the number of claims and continuations that patent applicants ...

Share via E–mail | Twitter | Facebook

Plagiarism in the law: gambling in Casablanca? from

On Oct. 9, 2009, the Australian reported: Attorney-General Cameron Dick has warned that the plagiarism scandal now racking the Queensland Law Society could tarnish the reputation of all legal practitioners.

On Oct. 6, 2009, a ...

Share via E–mail | Twitter | Facebook

IBM calls for swift passage of patent reform from

From a press release on October 9, 2009:

IBM today called for swift passage of patent reform legislation, describing it as essential to
enabling the nation's continued innovation leadership, bolstering U.S.
competitiveness in ...

Share via E–mail | Twitter | Facebook

Pressure to constantly publish new work? from

IPBiz had to re-post this description of "college professor jobs" from

3. College Professor

Median salary (experienced): $70,400
Top pay: $115,000
Job growth (10-year forecast): 23%
Sector: Education

What they do ...

Share via E–mail | Twitter | Facebook

"Catch-All" Description of "Authors and Inventors of Prior Art" Does Not Satisfy FRCP 26 Obligation from

The court granted plaintiff's motion to exclude the testimony of authors/inventors of prior art where defendant's FRCP 26 disclosures failed to identify the witnesses by name and instead identified them by the ...

Share via E–mail | Twitter | Facebook

The Rules Are Dead. Long Live The Rules! from

Under Secretary of Commerce for Intellectual Property and Director of the USPTO David Kappos has officially rescinded the highly hated regulations that would have limited patented claims and continuations — with an emphasis on the fact ...

Share via E–mail | Twitter | Facebook

Minority Report: Task Force on IP & Genetic Testing from

Yesterday, the Task Force on IP and Genetic Testing submitted its Final Draft Report (titled Final Draft Report on Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests) to the ...

Share via E–mail | Twitter | Facebook

Kappos Rescinds Claims & Continuations Rules, What Next? from

By now most are likely aware of, or rapidly becoming aware of, the fact that the United States Patent and Trademark Office has finally done the right thing and has scrapped the claims and continuations ...

Share via E–mail | Twitter | Facebook

NIH Shocked To Find Patents Work As Expected from

The NIH Office of Biotechnology Activities (OBA) tries to promote science, safety, and ethics in biotechnology through advancement of knowledge, enhancement of public understanding, and development of public policies. The OBA manages the Secretary’s ...

Share via E–mail | Twitter | Facebook

What happened to Dr. Triantafyllos Tafas? from

In an article titled New Chief of Patent Office Takes Aim at a Massive Backlog , AMY SCHATZ writes:

U.K. drug maker GlaxoSmithKline PLC challenged the Bush administration's rules in federal court in 2007 ...

Share via E–mail | Twitter | Facebook

Some content © 2007–2014 RPX Corporation.
Terms of Service & Privacy Policy
For DMCA requests contact